View in EDS HTML Full Text PDF Full Text

Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy.

Saved in:
Bibliographic Details
Title: Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy.
Authors: Li G; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Li W; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Wang L; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Bi Y; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Wang Y; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Zheng X; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Hao R; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Yin Y; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Yu Y; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Mu H; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Li J; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Ma X; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Zhou S; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Han J; Tasly Biopharmaceuticals Co., Ltd., Tianjin, China., Wang G; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Huang R; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.
Source: Frontiers in immunology [Front Immunol] 2026 Jan 12; Vol. 16, pp. 1691774. Date of Electronic Publication: 2026 Jan 12 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41601637
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+G%22">Li G</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Li+W%22">Li W</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Bi+Y%22">Bi Y</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Zheng+X%22">Zheng X</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Hao+R%22">Hao R</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Yin+Y%22">Yin Y</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Yu+Y%22">Yu Y</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Mu+H%22">Mu H</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Ma+X%22">Ma X</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Zhou+S%22">Zhou S</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Han+J%22">Han J</searchLink>; Tasly Biopharmaceuticals Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Wang+G%22">Wang G</searchLink>; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Huang+R%22">Huang R</searchLink>; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Jan 12; Vol. 16, pp. 1691774. <i>Date of Electronic Publication: </i>2026 Jan 12 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41601637
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2025.1691774
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1691774
    Titles:
      – TitleFull: Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li G
      – PersonEntity:
          Name:
            NameFull: Li W
      – PersonEntity:
          Name:
            NameFull: Wang L
      – PersonEntity:
          Name:
            NameFull: Bi Y
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Zheng X
      – PersonEntity:
          Name:
            NameFull: Hao R
      – PersonEntity:
          Name:
            NameFull: Yin Y
      – PersonEntity:
          Name:
            NameFull: Yu Y
      – PersonEntity:
          Name:
            NameFull: Mu H
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Ma X
      – PersonEntity:
          Name:
            NameFull: Zhou S
      – PersonEntity:
          Name:
            NameFull: Han J
      – PersonEntity:
          Name:
            NameFull: Wang G
      – PersonEntity:
          Name:
            NameFull: Huang R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 01
              Text: 2026 Jan 12
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1